Accession Number : AD1036002


Title :   Using T2-Exchange from Ln3+DOTA-Based Chelates for Contrast-Enhanced Molecular Imaging of Prostate Cancer with MRI


Descriptive Note : Technical Report,01 Feb 2014,31 Jan 2016


Corporate Author : University of Texas, Southwestern Medical Center at Dallas Dallas United States


Personal Author(s) : Soesbe,Todd C ; Wu,Yunkou ; Ratnakar,James ; Milne,Mark ; Zhang,Lei ; Sherry,A D


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1036002.pdf


Report Date : 01 Apr 2016


Pagination or Media Count : 22


Abstract : Purpose: To develop a targeted T2-exchange MRI contrast agent for the early detection and diagnosis of prostate cancer. Scope: This contrast agent is based on T2 contrast (i.e., hypo-intense contrast) arising from water molecule exchange between the inner-sphere of a Dysprosium (Dy3+) central ion and the bulk water. The level of this T2-exchange contrast is highly dependent on both the water molecule exchange rate and the paramagnetic shift of the water molecule hydrogen protons when bound to the Dy3+ ion. After identifying which DyDOTA-based chelate gave the optimal water molecule exchange rate at 9.4 T MRI, the chelate would then be polymerized to increase the transverse relaxivity (r2) per molecule by 100 fold. Thereby creating a highly sensitive, low molecular weight T2 contrast agent for cancer molecular imaging with MRI. Polymers targeting the prostate specific membrane antigen (PSMA) of prostate cancer cells would then be synthesized and tested with both in vitro and in vivo experiments.


Descriptors :   magnetic resonance imaging , prostate cancer , ionizing radiation , metal oxide nanoparticles , high resolution , chemical shifts , albumins , nanoparticles , lanthanides , chemical analysis , tissues (biology) , biological detection


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE